Dr. Yesmean Wahdan

Christine Roth, Executive Vice President at Bayer Pharmaceuticals, teams up with Dr. Yesmean Wahdan, Senior VP of Medical Affairs, to discuss Bayer's revolutionary Dynamic Shared Ownership model. They highlight how breaking down hierarchies enhances collaboration between R&D and commercialization, speeding up innovation. Their approach has notably shortened regulatory timelines and ensured patient needs are prioritized. With real-world evidence and early market insights, Bayer is transforming drug development to deliver treatments faster and more efficiently.